GGrantIndex
← Leaderboards

Stanley Lipkowitz

Division Of Basic Sciences - Nci

$260,385
Attributed
$1,041,539
Total exposure
1
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $592.6K · FY202223
$1M$750K$500K$250K$0
'22
'23

Funding mix

By agency

NIH$1,041,539 · 1

By mechanism

U01$1,041,539 · 1

Top collaborators

Most similar at Division Of Basic Sciences - Nci

Same institution · by research overlap

Others in their field

Other Rising Stars on “Malignant Breast Neoplasm

Research focus

Malignant Breast NeoplasmMediatingTumorMemberMalignant NeoplasmsCollaborationsMutationProteinsClinical TrialsErbb2 GeneCancer CellBreast Cancer PatientApoptosisProtein Tyrosine KinaseCellsEpidermal Growth Factor ReceptorSignal TransductionReceptorCessation Of LifeResistanceBreast Cancer CellLigandsPre-ClinicalCell Death

Grant awards (51)

Activating Cell Death Pathways in Breast Cancer Cells$1,213,551
ZIA · FY2025 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$772,260
ZIA · FY2025 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$220,646
ZIA · FY2025 · CA · contact PI
Activating Cell Death Pathways in Breast Cancer Cells$1,252,350
ZIA · FY2024 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$796,950
ZIA · FY2024 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$227,701
ZIA · FY2024 · CA · contact PI
Activating Cell Death Pathways in Breast Cancer Cells$1,045,773
ZIA · FY2023 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$665,492
ZIA · FY2023 · CA · contact PI
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)$592,634
U01 · FY2023 · CA
Genomic characterization of breast cancer in high risk subsets of breast cancer$190,141
ZIA · FY2023 · CA · contact PI
Activating Cell Death Pathways in Breast Cancer Cells$1,018,140
ZIA · FY2022 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$647,907
ZIA · FY2022 · CA · contact PI
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)$448,905
U01 · FY2022 · CA
Genomic characterization of breast cancer in high risk subsets of breast cancer$185,117
ZIA · FY2022 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$867,532
ZIA · FY2021 · CA · contact PI
Activating Cell Death Pathways in Breast Cancer Cells$867,532
ZIA · FY2021 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$192,785
ZIA · FY2021 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$790,617
ZIA · FY2020 · CA · contact PI
Activating Cell Death Pathways in Breast Cancer Cells$790,617
ZIA · FY2020 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$175,693
ZIA · FY2020 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$724,562
ZIA · FY2019 · CA · contact PI
Activating Cell Death Pathways in Breast Cancer Cells$724,562
ZIA · FY2019 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$161,014
ZIA · FY2019 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$662,171
ZIA · FY2018 · CA · contact PI
Activating Cell Death Pathways in Breast Cancer Cells$662,171
ZIA · FY2018 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$147,149
ZIA · FY2018 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$730,319
ZIA · FY2017 · CA · contact PI
Activating Cell Death Pathways in Breast Cancer Cells$730,319
ZIA · FY2017 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$162,293
ZIA · FY2017 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$784,437
ZIA · FY2016 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$784,437
ZIA · FY2016 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$174,319
ZIA · FY2016 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$827,183
ZIA · FY2015 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$496,310
ZIA · FY2015 · CA · contact PI
Genomic characterization of breast cancer in high risk subsets of breast cancer$330,873
ZIA · FY2015 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$1,001,335
ZIA · FY2014 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$493,195
ZIA · FY2014 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$981,727
ZIA · FY2013 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$245,431
ZIA · FY2013 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$955,212
ZIA · FY2012 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$238,803
ZIA · FY2012 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$765,435
ZIA · FY2011 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$377,005
ZIA · FY2011 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$805,924
ZIA · FY2010 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$433,959
ZIA · FY2010 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$612,110
ZIA · FY2009 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$428,477
ZIA · FY2009 · CA · contact PI
Identification of Molecular Targets in Triple-Negative Breast Cancer$183,633
ZIA · FY2009 · CA · contact PI
Cbl Proteins as Regulators of Tyrosine Kinase Signaling$619,015
Z01 · FY2008 · CA · contact PI
TRAIL-induced Cell Death in Breast Cancer Cells$433,310
Z01 · FY2008 · CA · contact PI
Identification of Molecular Targets in Triple-Negative Breast Cancer$185,704
Z01 · FY2008 · CA · contact PI